<p>Eyepoint Pharmaceuticals, Inc.（納斯達克代碼：EYPT - 獲取免費報告）週一股價上漲了 8.6%。該公司股價最高達到 12.46 美元，最後交易價格為 12.58 美元。在午盤交易中，交易量為 292,616 股，較平均交易量 911,497 股下降了 68%。該股票之前的收盤價為 11.58 美元。</p>
<h2>華爾街分析師觀點</h2>
<ul>
<li>你可能不知道的突破性動量股</li>
</ul>
<p>幾家研究公司最近對 EYPT 進行了評估。HC Wainwright 將 Eyepoint Pharmaceuticals 的目標價格從 22.00 美元上調至 23.00 美元，並在 8 月 6 日的研究報告中給予該公司 “買入” 評級。Chardan Capital 在 8 月 7 日的研究報告中重申了 “買入” 評級，並對 Eyepoint Pharmaceuticals 的股票設定了 27.00 美元的目標價格。Mizuho 在 10 月 20 日的研究報告中對 Eyepoint Pharmaceuticals 的股票設定了 28.00 美元的目標價格。加拿大皇家銀行在 11 月 6 日的研究報告中將 Eyepoint Pharmaceuticals 的目標價格從 28.00 美元上調至 39.00 美元，並給予該公司 “跑贏大盤” 評級。最後，Weiss Ratings 在 10 月 8 日的研究報告中重申了 Eyepoint Pharmaceuticals 的 “賣出（d-）” 評級。五位股票研究分析師對該股票給予了 “買入” 評級，一位分析師給予了 “賣出” 評級。根據 MarketBeat 的數據，該股票目前的共識評級為 “適度買入”，平均目標價格為 30.00 美元。</p>
<p><strong>獲取我們關於 Eyepoint Pharmaceuticals 的最新股票報告</strong></p>
<h2>Eyepoint Pharmaceuticals 股價上漲 12.3%</h2>
<p>該股票的市值為 10.8 億美元，市盈率為-4.84，貝塔值為 1.85。該公司的 50 日移動平均線為 12.76 美元，200 日移動平均線為 10.49 美元。</p>
<p>Eyepoint Pharmaceuticals（納斯達克代碼：EYPT - 獲取免費報告）最近於 11 月 5 日發佈了季度財報。該公司報告季度每股收益為（0.85 美元），低於分析師共識預期的（0.77 美元）0.08 美元。該公司季度收入為 97 萬美元，而分析師預期為 333 萬美元。Eyepoint Pharmaceuticals 的股本回報率為-63.80%，淨利潤率為-337.93%。整體來看，股票分析師預計 Eyepoint Pharmaceuticals, Inc.在本財年的每股收益將為-2.13 美元。</p>
<h2>機構投資者對 Eyepoint Pharmaceuticals 的看法</h2>
<p>對沖基金最近對該公司的持倉進行了調整。Nisa Investment Advisors LLC 在第二季度將其在 Eyepoint Pharmaceuticals 的持股增加了 1,636.5%。Nisa Investment Advisors LLC 目前擁有 2900 股該公司的股票，價值 27,000 美元，此前在上個季度購買了 2733 股。阿拉斯加州財政部在第三季度購買了 Eyepoint Pharmaceuticals 的新股份，價值約 50,000 美元。Russell Investments Group Ltd.在第三季度獲得了 Eyepoint Pharmaceuticals 的新持倉，價值約 76,000 美元。Tower Research Capital LLC TRC 在第二季度將其在 Eyepoint Pharmaceuticals 的持股增加了 218.3%。Tower Research Capital LLC TRC 目前擁有 8700 股該公司的股票，價值 82,000 美元，此前在此期間又購買了 5967 股。最後，R Squared Ltd 在第二季度獲得了 Eyepoint Pharmaceuticals 的新股份，價值約 100,000 美元。機構投資者和對沖基金持有該公司 99.41% 的股票。</p>
<h2>Eyepoint Pharmaceuticals 公司簡介</h2>
<p>（獲取免費報告）</p>
<p>EyePoint Pharmaceuticals, Inc.是一家臨牀階段的生物製藥公司，致力於開發和商業化治療方案，以改善嚴重視網膜疾病患者的生活。該公司的產品線利用其專有的生物可降解 Durasert E 技術進行持續的眼內藥物輸送。</p>
<h2>瞭解更多</h2>
<ul>
<li>我們更看好的五隻股票，優於 Eyepoint Pharmaceuticals</li>
<li>電話會議和個人投資者</li>
<li>巴菲特減持蘋果，退休前重注 Alphabet</li>
<li>低市盈率成長股：解鎖投資機會</li>
<li>三家能源巨頭提高股息——這對投資者意味着什麼</li>
<li>兩隻上升的 CRM 平台股票，可能在 2025 年大幅上漲</li>
<li>為什麼這三隻科技股可能是你忽視的最佳機會</li>
</ul>
<p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元在 Eyepoint Pharmaceuticals 嗎？</h2>
<p>在考慮 Eyepoint Pharmaceuticals 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦的股票。MarketBeat 已識別出五隻頂級分析師正在悄悄向客户推薦的股票，以便在更廣泛的市場注意到之前購買……而 Eyepoint Pharmaceuticals 並不在名單上。</p>
<p>雖然 Eyepoint Pharmaceuticals 目前在分析師中獲得了適度買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

EYPT

<p>Eyepoint Pharmaceuticals（納斯達克代碼：EYPT）股價上漲 8.6%，至 12.58 美元，交易量有所下降。分析師給予 “適度買入” 評級，目標價格範圍為 23 美元至 39 美元。該公司報告的季度每股收益為（0.85 美元），未達到預期，收入為 97 萬美元。機構投資者已調整其持倉，持有 99.41% 的股份。Eyepoint 專注於使用 Durasert E 技術治療視網膜疾病</p>

<p>Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Get Free Report) shares shot up 8.6% on Monday . The company traded as high as $12.46 and last traded at $12.58. 292,616 shares were traded during mid-day trading, a decline of 68% from the average session volume of 911,497 shares. The stock had previously closed at $11.58.</p>
<div class="lb-trans"><p>Eyepoint Pharmaceuticals, Inc.（納斯達克代碼：EYPT - 獲取免費報告）週一股價上漲了 8.6%。該公司股價最高達到 12.46 美元，最後交易價格為 12.58 美元。在午盤交易中，交易量為 292,616 股，較平均交易量 911,497 股下降了 68%。該股票之前的收盤價為 11.58 美元。</p>
</div><h2>Wall Street Analyst Weigh In</h2>
<div class="lb-trans"><h2>華爾街分析師觀點</h2>
</div><ul>
<li>Breakout Momentum Plays You May Not Know About</li>
</ul>
<div class="lb-trans"><ul>
<li>你可能不知道的突破性動量股</li>
</ul>
</div><p>Several research firms recently weighed in on EYPT. HC Wainwright raised their price objective on Eyepoint Pharmaceuticals from $22.00 to $23.00 and gave the company a &#34;buy&#34; rating in a research note on Wednesday, August 6th. Chardan Capital restated a &#34;buy&#34; rating and issued a $27.00 price target on shares of Eyepoint Pharmaceuticals in a research report on Thursday, August 7th. Mizuho set a $28.00 price objective on shares of Eyepoint Pharmaceuticals in a research report on Monday, October 20th. Royal Bank Of Canada increased their price objective on shares of Eyepoint Pharmaceuticals from $28.00 to $39.00 and gave the company an &#34;outperform&#34; rating in a research note on Thursday, November 6th. Finally, Weiss Ratings restated a &#34;sell (d-)&#34; rating on shares of Eyepoint Pharmaceuticals in a research report on Wednesday, October 8th. Five equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company's stock. According to MarketBeat, the stock currently has a consensus rating of &#34;Moderate Buy&#34; and an average price target of $30.00.</p>
<div class="lb-trans"><p>幾家研究公司最近對 EYPT 進行了評估。HC Wainwright 將 Eyepoint Pharmaceuticals 的目標價格從 22.00 美元上調至 23.00 美元，並在 8 月 6 日的研究報告中給予該公司 “買入” 評級。Chardan Capital 在 8 月 7 日的研究報告中重申了 “買入” 評級，並對 Eyepoint Pharmaceuticals 的股票設定了 27.00 美元的目標價格。Mizuho 在 10 月 20 日的研究報告中對 Eyepoint Pharmaceuticals 的股票設定了 28.00 美元的目標價格。加拿大皇家銀行在 11 月 6 日的研究報告中將 Eyepoint Pharmaceuticals 的目標價格從 28.00 美元上調至 39.00 美元，並給予該公司 “跑贏大盤” 評級。最後，Weiss Ratings 在 10 月 8 日的研究報告中重申了 Eyepoint Pharmaceuticals 的 “賣出（d-）” 評級。五位股票研究分析師對該股票給予了 “買入” 評級，一位分析師給予了 “賣出” 評級。根據 MarketBeat 的數據，該股票目前的共識評級為 “適度買入”，平均目標價格為 30.00 美元。</p>
</div><p><strong>Get Our Latest Stock Report on Eyepoint Pharmaceuticals</strong></p>
<div class="lb-trans"><p><strong>獲取我們關於 Eyepoint Pharmaceuticals 的最新股票報告</strong></p>
</div><h2>Eyepoint Pharmaceuticals Trading Up 12.3%</h2>
<div class="lb-trans"><h2>Eyepoint Pharmaceuticals 股價上漲 12.3%</h2>
</div><p>The stock has a market cap of $1.08 billion, a price-to-earnings ratio of -4.84 and a beta of 1.85. The firm's 50 day moving average is $12.76 and its two-hundred day moving average is $10.49.</p>
<div class="lb-trans"><p>該股票的市值為 10.8 億美元，市盈率為-4.84，貝塔值為 1.85。該公司的 50 日移動平均線為 12.76 美元，200 日移動平均線為 10.49 美元。</p>
</div><p>Eyepoint Pharmaceuticals (NASDAQ:EYPT - Get Free Report) last issued its quarterly earnings results on Wednesday, November 5th. The company reported ($0.85) EPS for the quarter, missing analysts' consensus estimates of ($0.77) by ($0.08). The firm had revenue of $0.97 million for the quarter, compared to analysts' expectations of $3.33 million. Eyepoint Pharmaceuticals had a negative return on equity of 63.80% and a negative net margin of 337.93%. As a group, equities analysts expect that Eyepoint Pharmaceuticals, Inc. will post -2.13 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>Eyepoint Pharmaceuticals（納斯達克代碼：EYPT - 獲取免費報告）最近於 11 月 5 日發佈了季度財報。該公司報告季度每股收益為（0.85 美元），低於分析師共識預期的（0.77 美元）0.08 美元。該公司季度收入為 97 萬美元，而分析師預期為 333 萬美元。Eyepoint Pharmaceuticals 的股本回報率為-63.80%，淨利潤率為-337.93%。整體來看，股票分析師預計 Eyepoint Pharmaceuticals, Inc.在本財年的每股收益將為-2.13 美元。</p>
</div><h2>Institutional Investors Weigh In On Eyepoint Pharmaceuticals</h2>
<div class="lb-trans"><h2>機構投資者對 Eyepoint Pharmaceuticals 的看法</h2>
</div><p>Hedge funds have recently made changes to their positions in the business. Nisa Investment Advisors LLC increased its stake in Eyepoint Pharmaceuticals by 1,636.5% in the second quarter. Nisa Investment Advisors LLC now owns 2,900 shares of the company's stock valued at $27,000 after purchasing an additional 2,733 shares during the last quarter. State of Alaska Department of Revenue purchased a new stake in Eyepoint Pharmaceuticals in the 3rd quarter valued at about $50,000. Russell Investments Group Ltd. acquired a new position in shares of Eyepoint Pharmaceuticals during the 3rd quarter valued at about $76,000. Tower Research Capital LLC TRC lifted its holdings in shares of Eyepoint Pharmaceuticals by 218.3% during the 2nd quarter. Tower Research Capital LLC TRC now owns 8,700 shares of the company's stock worth $82,000 after acquiring an additional 5,967 shares during the period. Finally, R Squared Ltd acquired a new stake in shares of Eyepoint Pharmaceuticals in the second quarter worth approximately $100,000. Institutional investors and hedge funds own 99.41% of the company's stock.</p>
<div class="lb-trans"><p>對沖基金最近對該公司的持倉進行了調整。Nisa Investment Advisors LLC 在第二季度將其在 Eyepoint Pharmaceuticals 的持股增加了 1,636.5%。Nisa Investment Advisors LLC 目前擁有 2900 股該公司的股票，價值 27,000 美元，此前在上個季度購買了 2733 股。阿拉斯加州財政部在第三季度購買了 Eyepoint Pharmaceuticals 的新股份，價值約 50,000 美元。Russell Investments Group Ltd.在第三季度獲得了 Eyepoint Pharmaceuticals 的新持倉，價值約 76,000 美元。Tower Research Capital LLC TRC 在第二季度將其在 Eyepoint Pharmaceuticals 的持股增加了 218.3%。Tower Research Capital LLC TRC 目前擁有 8700 股該公司的股票，價值 82,000 美元，此前在此期間又購買了 5967 股。最後，R Squared Ltd 在第二季度獲得了 Eyepoint Pharmaceuticals 的新股份，價值約 100,000 美元。機構投資者和對沖基金持有該公司 99.41% 的股票。</p>
</div><h2>Eyepoint Pharmaceuticals Company Profile</h2>
<div class="lb-trans"><h2>Eyepoint Pharmaceuticals 公司簡介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>EyePoint Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery.</p>
<div class="lb-trans"><p>EyePoint Pharmaceuticals, Inc.是一家臨牀階段的生物製藥公司，致力於開發和商業化治療方案，以改善嚴重視網膜疾病患者的生活。該公司的產品線利用其專有的生物可降解 Durasert E 技術進行持續的眼內藥物輸送。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>瞭解更多</h2>
</div><ul>
<li>Five stocks we like better than Eyepoint Pharmaceuticals</li>
<li>Conference Calls and Individual Investors</li>
<li>Buffett Trims Apple, Bets Big on Alphabet Ahead of Retirement</li>
<li>Low PE Growth Stocks: Unlocking Investment Opportunities</li>
<li>3 Energy Giants Amp Up Dividends—Here’s What It Means for Investors</li>
<li>2 Rising CRM Platform Stocks That Can Surge Higher in 2025</li>
<li>Why These 3 Tech Stocks Could Be the Best Opportunities You're Overlooking</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票，優於 Eyepoint Pharmaceuticals</li>
<li>電話會議和個人投資者</li>
<li>巴菲特減持蘋果，退休前重注 Alphabet</li>
<li>低市盈率成長股：解鎖投資機會</li>
<li>三家能源巨頭提高股息——這對投資者意味着什麼</li>
<li>兩隻上升的 CRM 平台股票，可能在 2025 年大幅上漲</li>
<li>為什麼這三隻科技股可能是你忽視的最佳機會</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Eyepoint Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 Eyepoint Pharmaceuticals 嗎？</h2>
</div><p>Before you consider Eyepoint Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 Eyepoint Pharmaceuticals 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Eyepoint Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦的股票。MarketBeat 已識別出五隻頂級分析師正在悄悄向客户推薦的股票，以便在更廣泛的市場注意到之前購買……而 Eyepoint Pharmaceuticals 並不在名單上。</p>
</div><p>While Eyepoint Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Eyepoint Pharmaceuticals 目前在分析師中獲得了適度買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Eyepoint Pharmaceuticals（NASDAQ:EYPT）股價上漲 8.6% - 事件詳情如下